Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Obsessive-compulsive disorder

Obsessive-compulsive disorder

9 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Obsessive-compulsive disorder

56 trials tracked for Obsessive-compulsive disorder: 13 in phase 3 or 4 and 3 with published results. The most-cited published study has 124 citations.

56Trials tracked
13Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 3 Phase 3 10 Phase 2 19 Other / NA 24
  1. Phase 3 Intravenous Immunoglobulin for PANDAS Completed · 124 cited
  2. Phase 3 Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder Completed · 91 cited
  3. Phase 4 Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD) Completed · 19 cited
  4. Phase 4 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Completed
  5. Phase 4 Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder Completed
  6. Phase 3 A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder Completed
Show 44 more trials
  1. Phase 3 D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD) Completed
  2. Phase 3 Tolcapone in Obsessive Compulsive Disorder Completed
  3. Phase 3 Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder Completed
  4. Phase 3 A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder Completed
  5. Phase 3 Treatment of Obsessive Compulsive Disorder in Children Completed
  6. Phase 3 Effectiveness of D-Cycloserine as an Aid to Enhance Learning for Individuals With OCD Receiving Behavior Therapy Completed
  7. Phase 3 Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders Completed
  8. Phase 2 Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder Completed
  9. Phase 2 Oxytocin Administration in BDD and OCD Completed
  10. Phase 2 Ketamine Infusion for Obsessive-Compulsive Disorder Completed
  11. Phase 2 Transcranial Magnetic Stimulation (TMS) and Obsessive Compulsive Disorder (OCD) Completed
  12. Phase 2 Videophone Administered Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder Completed
  13. Phase 2 Pilot Study of Minocycline (NPL-2003) in Adults With Obsessive-Compulsive Disorder (OCD) Completed
  14. Phase 2 Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders Completed
  15. Phase 2 Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder Completed
  16. Phase 2 Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD Completed
  17. Phase 2 Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP) Completed
  18. Phase 2 Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder Completed
  19. Phase 2 N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder Completed
  20. Phase 2 Effects of Marijuana on Symptoms of OCD Completed
  21. Phase 2 Cannabinoid Medication for Adults With OCD Completed
  22. Phase 2 Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD) Completed
  23. Phase 2 Memantine Augmentation in Obsessive-Compulsive Disorder Completed
  24. Phase 2 D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder Completed
  25. Phase 2 Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD) Completed
  26. Phase 2 Marinol in Trichotillomania or Obsessive Compulsive Disorder Completed
  27. N/A Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD Completed
  28. N/A Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders Completed
  29. N/A Transcranial Magnetic Stimulation (TMS) in Obsessive Compulsive Disorder (OCD): Mechanisms and Biomarkers Completed
  30. N/A Stepped-Care Cognitive-Behavioral Treatment for Youth With ASD and Anxiety Completed
  31. N/A Dealing With Intrusive Thoughts in OCD - a Comparison of Detached Mindfulness and Cognitive Restructuring Completed
  32. N/A Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety Completed
  33. N/A Overlapping Neural Circuits in Pediatric OCD Completed
  34. N/A Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder Completed
  35. N/A Stepped Care for Treating Obsessive-Compulsive Disorder Completed
  36. N/A Improving Attentional and Cognitive Control in the Psychological Treatment of Intrusive Thoughts Completed
  37. N/A D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD Completed
  38. N/A Effectiveness and Neuropsychological Predictors of Guided Self-Help for Obsessive-Compulsive Disorder (OCD) Completed
  39. N/A Developing Effective Response Inhibition Training for Symptom Relief in OCD and Trichotillomania Completed
  40. N/A Transcranial Direct Current Stimulation Augmented Exposure and Response Prevention for Obsessive-Compulsive Disorder Completed
  41. N/A Virtual Reality System for Anxiety and OCD Completed
  42. N/A TMS for Improving Response Inhibition in Adolescents With OCD Completed
  43. N/A Digital Health Interventions for Obsessive Compulsive Disorder (OCD) Completed
  44. N/A Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES) Completed

Showing the 50 most-cited and recently-updated of 56 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Obsessive-compulsive disorder: what the trials found

Several pharmacological interventions have been evaluated for OCD symptoms. Fluvoxamine maleate demonstrated a statistically significant reduction in the Japanese Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) 10-item total score at the end of the first phase of treatment 11.

Memantine was investigated across multiple trials; while one study reported specific Y-BOCS changes from baseline over 12 weeks 22, another trial showed no significant difference in clinical responder rates or CY-BOCS scores 6. Other established pharmacological agents include Duloxetine 3, Ondansetron 4, d-cycloserine 10, and Tolcapone 9.

Non-pharmacological interventions, such as Cognitive-behavioral therapy 12 and Serotonin reuptake inhibitors management 13, are established in the literature. Other investigated agents include seromycin 14 and Troriluzole, though the latter showed no statistically significant improvement in Y-BOCS scores across two different trials [1, 8].

Recent results — preliminary, needs further review

  • Emotion Regulation Therapy - Attention Regulation (AR-ERT) was evaluated for transdiagnostic symptoms; however, results for repetitive negative thinking, worry, and rumination did not reach statistical significance 2.

For the clinician treating this condition

  • Fluvoxamine maleate is associated with a statistically significant reduction in JCY-BOCS scores in pediatric populations 11.
  • Evidence for Memantine is mixed, with some data showing changes in Y-BOCS scores while other trials showed no significant improvement in clinical responders or CY-BOCS scores [6, 21, 22].
  • Troriluzole did not demonstrate a statistically significant reduction in Y-BOCS scores in the evaluated studies [1, 8].

AI synthesis of 11 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Preliminary evidence suggests therapeutic drug monitoring of sertraline may guide clinical judgment in specific populations
Drug Pipeline Meta-analysis
Preliminary evidence suggests therapeutic drug monitoring of sertraline may guide clinical judgment in specific populations TDM Monitoring May Help Guide Sertraline Use for OCD Patients
This scoping review examined the clinical utility of sertraline therapeutic drug monitoring (TDM) for individuals with depression and obsess…
Monitoring blood levels of the medication sertraline might help doctors manage treatment for patients with depression and obsessive-compulsi…
Frontiers Jul 25, 2026
Acupoint stimulation reduces OCD symptoms by 3.14 points on Y-BOCS in meta-analysis
Neurology Meta-analysis
Acupoint stimulation reduces OCD symptoms by 3.14 points on Y-BOCS in meta-analysis Acupoint stimulation shows reduction in obsessive-compulsive disorder symptoms
A meta-analysis of 23 RCTs with 1,713 participants found that acupoint stimulation (electroacupuncture, acupuncture, transcutaneous electric…
New analysis of 23 trials suggests that acupoint stimulation can help reduce symptoms for people living with obsessive-compulsive disorder.
Frontiers Jul 23, 2026
Heterogeneous ASD phenotypes and inadequate sensory criteria necessitate more robust diagnostic assessment standards
Psychiatry Sys. Review
Heterogeneous ASD phenotypes and inadequate sensory criteria necessitate more robust diagnostic assessment standards New research highlights two distinct types of autism spectrum disorder
This narrative review examines the diagnostic validity, phenotypic heterogeneity, and assessment methodologies for Autism Spectrum Disorder …
Current diagnostic tools may miss many people with autism because they do not account for different ways the condition presents in daily lif…
Frontiers Jul 9, 2026
Deep learning model identifies neural connectivity patterns in patients with obsessive-compulsive disorder
Psychiatry Cohort
Deep learning model identifies neural connectivity patterns in patients with obsessive-compulsive disorder AI model identifies brain connectivity patterns in OCD
Researchers utilized a transformer-based deep learning model to analyze brain connectivity in individuals with obsessive-compulsive disorder…
New deep learning technology can identify specific patterns of reduced brain connectivity linked to obsessive-compulsive disorder.
medRxiv Apr 27, 2026
Narrative review proposes connectomic-guided psychosurgery framework for treatment-refractory patients
Psychiatry Sys. Review
Narrative review proposes connectomic-guided psychosurgery framework for treatment-refractory patients Researchers report framework for psychosurgery in treatment-refractory cases
This narrative critical review synthesizes contemporary psychosurgery options for treatment-refractory psychiatric disorders.
A new framework proposes connectomic-guided psychosurgery for treatment-refractory OCD, depression, and related disorders, based on symptom …
Frontiers Apr 23, 2026
WGS in multiplex OCD pedigrees identifies rare variants in NPY5R, DLGAP1, and MAPK8IP3
Psychiatry Case-Control
WGS in multiplex OCD pedigrees identifies rare variants in NPY5R, DLGAP1, and MAPK8IP3 OCD Genes Found in Family Clusters
This case report performed whole genome sequencing in 25 individuals from two multiplex OCD pedigrees to identify rare protein-disrupting va…
Imagine a family where multiple members — parents, children, siblings — all struggle with obsessive thoughts and compulsive rituals.
medRxiv Apr 22, 2026
Meta-analysis of connectome-based fMRI models shows high diagnostic accuracy in obsessive-compulsive disorder
Radiology & Imaging Meta-analysis
Meta-analysis of connectome-based fMRI models shows high diagnostic accuracy in obsessive-compulsive disorder Brain Scan Pattern Can Spot OCD with High Accuracy
This meta-analysis evaluated connectome-based diagnostic models derived from resting-state fMRI in 563 individuals with obsessive-compulsive…
A new brain scan pattern can spot obsessive-compulsive disorder with high accuracy, offering a clear test for millions who currently struggl…
Apr 19, 2026
Meta-analysis finds large symptom reductions with Detached Mindfulness for OCD and panic disorder
Psychiatry Meta-analysis
Meta-analysis finds large symptom reductions with Detached Mindfulness for OCD and panic disorder Could a new mindfulness approach help reduce symptoms of OCD and panic disorder?
This systematic review and meta-analysis synthesized evidence on Detached Mindfulness as a stand-alone intervention for obsessive–compulsive…
A new mindfulness approach called Detached Mindfulness helped reduce symptoms of OCD and panic disorder while also lowering feelings of sadn…
Frontiers Apr 16, 2026
Deep brain stimulation of the anterior limb of the internal capsule reduced OCD symptoms in a small observational study
Psychiatry
Deep brain stimulation of the anterior limb of the internal capsule reduced OCD symptoms in a small observational study A Tiny Brain Signal May Show When OCD Treatment Is Working
This observational study evaluated deep brain stimulation (DBS) of the anterior limb of the internal capsule in 10 clinically responsive…
A drop in a specific brain wave signal may tell doctors when deep brain stimulation is finally easing severe obsessive-compulsive disorder s…
medRxiv Apr 16, 2026

Questions about Obsessive-compulsive disorder

Are there specific brain connections that show up in obsessive-compulsive disorder?

Yes, OCD is linked to specific brain connections, especially in the cortico-striato-thalamo-cortical (CSTC) loop and fronto-limbic networks, as shown by imaging studies.

Full answer →
Does deep brain stimulation help reduce symptoms of obsessive-compulsive disorder?

Deep brain stimulation (DBS) can reduce obsessive-compulsive disorder symptoms in severe, treatment-resistant cases, with studies showing an average 40% symptom decrease after six months.

Full answer →
Did whole genome sequencing find rare gene variants in obsessive-compulsive disorder families?

Yes, whole genome sequencing in OCD families found rare variants in NPY5R, DLGAP1, and MAPK8IP3, with additional rare variants identified in larger exome studies.

Full answer →